| Silverlake Best Care, Inc | |
| 1711 West Temple Street, Suite 6690, Los Angeles, California 90026 | |
| (213) 279-9949 | |
| Not Available |
| Name | Silverlake Best Care, Inc |
|---|---|
| Location | 1711 West Temple Street, Suite 6690, Los Angeles, California |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 559072 |
| Ownership Type | Proprietary |
| Service Area Zip Codes |
| NPI Number | 1427514058 |
| Organization Name | SILVERLAKE TOTAL CARE, INC. |
| Address | 1711 W Temple St Ste 6691, Los Angeles, CA 90026 |
| Phone Number | 323-784-9555 |
News Archive
Columbia Laboratories, Inc., today announced that it will adopt Juniper Pharmaceuticals, Inc. as its new corporate brand. The name change will become effective Friday, April 10, 2015, and the Company's common stock will begin trading on the Nasdaq Stock Exchange under the new ticker symbol — "JNP" — on Monday, April 13, 2015.
The FDA has approved Botulinum Toxin Type A (Botox) to treat severe underarm sweating known as "primary axillary hyperhidrosis" that cannot be managed by topical agents such as prescription antiperspirants. Botox has already been approved for several other purposes.
Redding, where the Valley meets Cascade foothills, and Victorville, in the Mojave Desert, have little in common but an unusual statistic: In each city, a hospital has reported alarming rates of a Third World nutritional disorder among its Medicare patients. Kwashiorkor - a Ghanaian word for "weaning sickness" - is a severe protein deficiency that almost exclusively afflicts impoverished children in developing countries, especially during famines, experts say.
Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEX™ (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANT™ (dexlansoprazole). The product is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.
The most frequent contributors to medication errors and adverse drug events in busy primary care practice offices are communication problems and lack of knowledge, according to a study of a prototype web-based medication error and adverse drug event reporting system.
› Verified 4 days ago
| NPI Number | 1639669658 |
| Organization Name | SILVERLAKE BEST CARE, INC. |
| Address | 1711 W Temple St Ste 6691, Los Angeles, CA 90026 |
| Phone Number | 213-279-9949 |
News Archive
Columbia Laboratories, Inc., today announced that it will adopt Juniper Pharmaceuticals, Inc. as its new corporate brand. The name change will become effective Friday, April 10, 2015, and the Company's common stock will begin trading on the Nasdaq Stock Exchange under the new ticker symbol — "JNP" — on Monday, April 13, 2015.
The FDA has approved Botulinum Toxin Type A (Botox) to treat severe underarm sweating known as "primary axillary hyperhidrosis" that cannot be managed by topical agents such as prescription antiperspirants. Botox has already been approved for several other purposes.
Redding, where the Valley meets Cascade foothills, and Victorville, in the Mojave Desert, have little in common but an unusual statistic: In each city, a hospital has reported alarming rates of a Third World nutritional disorder among its Medicare patients. Kwashiorkor - a Ghanaian word for "weaning sickness" - is a severe protein deficiency that almost exclusively afflicts impoverished children in developing countries, especially during famines, experts say.
Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEX™ (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANT™ (dexlansoprazole). The product is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.
The most frequent contributors to medication errors and adverse drug events in busy primary care practice offices are communication problems and lack of knowledge, according to a study of a prototype web-based medication error and adverse drug event reporting system.
› Verified 4 days ago
| Quality Rating: | Not Available* |
| * This measure currently does not have data or provider has been certified/recertified for less than 6 months. | |
News Archive
Columbia Laboratories, Inc., today announced that it will adopt Juniper Pharmaceuticals, Inc. as its new corporate brand. The name change will become effective Friday, April 10, 2015, and the Company's common stock will begin trading on the Nasdaq Stock Exchange under the new ticker symbol — "JNP" — on Monday, April 13, 2015.
The FDA has approved Botulinum Toxin Type A (Botox) to treat severe underarm sweating known as "primary axillary hyperhidrosis" that cannot be managed by topical agents such as prescription antiperspirants. Botox has already been approved for several other purposes.
Redding, where the Valley meets Cascade foothills, and Victorville, in the Mojave Desert, have little in common but an unusual statistic: In each city, a hospital has reported alarming rates of a Third World nutritional disorder among its Medicare patients. Kwashiorkor - a Ghanaian word for "weaning sickness" - is a severe protein deficiency that almost exclusively afflicts impoverished children in developing countries, especially during famines, experts say.
Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEX™ (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANT™ (dexlansoprazole). The product is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.
The most frequent contributors to medication errors and adverse drug events in busy primary care practice offices are communication problems and lack of knowledge, according to a study of a prototype web-based medication error and adverse drug event reporting system.
› Verified 4 days ago
News Archive
Columbia Laboratories, Inc., today announced that it will adopt Juniper Pharmaceuticals, Inc. as its new corporate brand. The name change will become effective Friday, April 10, 2015, and the Company's common stock will begin trading on the Nasdaq Stock Exchange under the new ticker symbol — "JNP" — on Monday, April 13, 2015.
The FDA has approved Botulinum Toxin Type A (Botox) to treat severe underarm sweating known as "primary axillary hyperhidrosis" that cannot be managed by topical agents such as prescription antiperspirants. Botox has already been approved for several other purposes.
Redding, where the Valley meets Cascade foothills, and Victorville, in the Mojave Desert, have little in common but an unusual statistic: In each city, a hospital has reported alarming rates of a Third World nutritional disorder among its Medicare patients. Kwashiorkor - a Ghanaian word for "weaning sickness" - is a severe protein deficiency that almost exclusively afflicts impoverished children in developing countries, especially during famines, experts say.
Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEX™ (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANT™ (dexlansoprazole). The product is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.
The most frequent contributors to medication errors and adverse drug events in busy primary care practice offices are communication problems and lack of knowledge, according to a study of a prototype web-based medication error and adverse drug event reporting system.
› Verified 4 days ago
Danny's Home Health Care, Inc Location: 1539 Sawtelle Blvd, Los Angeles, California 90025 Ratings: Phone: (818) 246-1342 | |
Liha Home Health Care, Inc Location: 3200 Wilshire Blvd, Suite 305, North Tower, Los Angeles, California 90010 Ratings: Phone: (213) 379-1363 | |
Glory Home Health, Inc Location: 5085 West Pico Blvd, Los Angeles, California 90019 Ratings: Phone: (626) 589-5289 | |
Maxim Healthcare Services Location: 3580 Wilshire Blvd, Suite 1000, Los Angeles, California 90010 Ratings: NA Phone: (213) 296-3477 | |
Dignity Home Health, Inc Location: 5300 Santa Monica Blvd Suite 412, Los Angeles, California 90029 Ratings: Phone: (818) 696-2223 | |
Nh Home Health Care, Inc Location: 5300 Santa Monica Blvd, Suite 207, Los Angeles, California 90029 Ratings: Phone: (747) 208-5400 |